he discovery of a novel antibiotic is just the beginning of a wave of potential new drugs being literally unearthed through breakthroughs in molecular technology, say researchers in Canada and the United States.
"We are now in a totally different universe," says Slava Epstein, a professor of biology at Northeastern University in Boston, Mass., and co-discoverer of teixobactin, a compound active against methicillin-resistant Staphylococcus aureus in mice as well as many Grampositive bacteria in culture. Found in a random soil sample, the antibiotic inhibits bacterial cell wall synthesis, which makes bacteria less likely to develop resistance to it. The discovery was published in Nature Jan. 7, 2015.
Epstein says this single discovery is the tip of the iceberg. The technology developed to find it can be used to search rapidly through tens of thousands of microbes previously inaccessible to researchers and find those useful to medicine. Not only antibiotics, but also antiviral and anticancer agents may be out there, and researchers have the tools to find them for the first time, adds Julian Davies, a researcher in the Department of Microbiology and Immunology at the University of British Columbia in Vancouver.
The find comes at a time that the World Health Organization has sounded the alarm over antimicrobial resistance, saying it is killing millions, driving up health care costs, and jeopardizing other progress in health care such as surgical treatment and chemotherapy.
Antibiotics that occur commonly in nature, such as streptomycin, have all been found, say researchers, and traditional sources in soils are "overmined." As a result, researchers have gone farther afield, even deep in the oceans, to find new compounds.
In a 2006 commentary in the Canadian Journal of Infectious Disease and Medical Microbiology, Davies bemoaned the lack of new discoveries since the antibiotic heyday of the 1950s. As resistance developed, the drug industry's "losing battle" with microbes led to "virtual resignation." But that's not the case today, says Davies.
What's changed is that scientists are finding ways to culture an estimated 95% to 99% of the microbes found in soils, the sea, and even the human microbiome that could not be cultured before. "You can go to the ends of the earth, or you can go to the same places, and then hunt down those hard-to-grow organisms and tame them," explains Gerry Wright, director of the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University in Hamilton, Ont., and author of a commentary in Nature on the teixobactin discovery. "It's a bit of a black art, I must confess. There's no easy recipe."
Researchers at Northeastern made two breakthroughs in "taming" these organisms, Epstein explains. Many natural environments in soils and the sea contain what Epstein calls a "zoo" of microbial colonies. In 2002, the Northeastern team developed a simple diffusion chamber with several "traps" to separate microbes. Compared with standard cultivation media, Epstein says "the difference was stunning." The original diffusion chamber was further developed to handle a high throughput, a device now called an "iChip." Wright explains that microbes from a natural environment are first diluted and then put onto the iChip, where each microbe crawls into a separate trap. This technology increases the odds of discovery.
Using traditional methods, Epstein says, about 10 million colonies would need to be screened to find one useful new antibiotic. But in their recent work, Kim Lewis and Epstein's team found 25 antimicrobial compounds in only 50 000 bacterial colonies, making "the pipeline economically more viable."
They also needed to overcome the challenge of culturing the vast majority of microbes that fail to grow in a lab. He and coauthor Lewis reasoned that they needed to give microbes "what they need" to survive, except that they didn't know what that was. The answer was to put the organisms back into their natural environment -the soil where they found them -and simply
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Northeastern University contain the organisms, originally in a regular dialysis bag. Initial attempts failed when the microbes ate the bag, so they found a polycarbonate membrane that worked.
The cultured microbes produce antimicrobial compounds. "A lot of the compounds we call antibiotics are signalling molecules," explains Davies. "They are how the bacteria communicate with each other."
Wright explains that stiff evolutionary competition among microbes results in resistance to these antibiotics, but also compounds that fight resistance. "If an organism develops an antibiotic, it has a competitive advantage in the environment, until the neighbour becomes resistant to that antibiotic. So now the original guy is out of luck, so it could evolve another antibiotic pathway or it could block resistance out there." The hope is that these resistance-blocking antibiotics could be put to use for humans.
And there are other new technologies leading to discovery. Davies mentions next-generation gene sequencing, which allows researchers to screen enormous collections of DNA from soils. These yield gene clusters, which can be put into other host organisms. "You don't isolate antibiotics as compounds from the soil; you isolate the pathways to make them."
Years to clinical use
Researchers caution that drugs from this promising research are still years away from clinical application. "This new paper [on teixobactin] is interesting, but I don't know whether the compound is going to be any good or not," says Davies. "We don't know anything about its toxicity and its mechanism of action."
Similarly, Wright's team has recently found a fungal antibiotic that "worked really well in animals, but we have to prove that it is safe and has no off-target effects." Hundreds to thousands of potential new drugs fail for every one that succeeds, and preclinical testing can last years. "Safety standards are quite rightly very strenuous."
To develop these novel compounds, Lewis and Epstein have founded a new company, and there are other start-ups working on the pipeline for these drugs. Researchers agree that entirely new classes of drugs will eventually become available. Doctors graduating today may be able to look forward to a new armamentarium during their careers. -Carolyn Brown, Ottawa, Ont.
